SST
KRYS icon

S Squared Technology’s Krystal Biotech KRYS Stock Holding History

S Squared Technology’s Portfolio KRYS Stock Details KRYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$22.3M Sell
86,215
-10,000
-10% -$2.66M 8.43% 2
2025
Q4 		$23.7M Sell
96,215
-13,000
-12% -$2.74M 9.19% 2
2025
Q3 		$19.3M Hold
109,215
– – 7.33% 2
2025
Q2 		$15M Buy
109,215
+12,000
+12% +$1.76M 6.33% 4
2025
Q1 		$17.5M Buy
97,215
+2,000
+2% +$336K 8.97% 1
2024
Q4 		$14.9M Buy
95,215
+20,000
+27% +$3.55M 6.2% 3
2024
Q3 		$13.7M Sell
75,215
-10,000
-12% -$1.93M 5.84% 4
2024
Q2 		$15.6M Sell
85,215
-5,000
-6% -$839K 6.91% 3
2024
Q1 		$16.1M Sell
90,215
-20,000
-18% -$2.78M 7.37% 2
2023
Q4 		$13.7M Buy
110,215
+2,000
+2% +$222K 6.64% 4
2023
Q3 		$12.6M Hold
108,215
– – 6.77% 3
2023
Q2 		$12.7M Hold
108,215
– – 6.29% 3
2023
Q1 		$8.66M Hold
108,215
– – 5.14% 7
2022
Q4 		$8.57M Hold
108,215
– – 5.8% 5
2022
Q3 		$7.54M Hold
108,215
– – 5.52% 7
2022
Q2 		$7.11M Hold
108,215
– – 4.92% 8
2022
Q1 		$7.2M Buy
108,215
+13,000
+14% +$811K 3.59% 12
2021
Q4 		$6.66M Buy
95,215
+10,000
+12% +$582K 2.98% 14
2021
Q3 		$4.45M Hold
85,215
– – 2.02% 20
2021
Q2 		$5.79M Hold
85,215
– – 2.62% 16
2021
Q1 		$6.57M Hold
85,215
– – 3.1% 12
2020
Q4 		$5.11M Buy
85,215
+5,000
+6% +$250K 2.93% 14
2020
Q3 		$3.45M Buy
80,215
+10,000
+14% +$434K 2.57% 15
2020
Q2 		$2.91M Buy
70,215
+10,000
+17% +$481K 2.28% 19
2020
Q1 		$2.6M Hold
60,215
– – 2.53% 15
2019
Q4 		$3.33M Sell
60,215
-7,318
-11% -$359K 2.74% 14
2019
Q3 		$2.35M Hold
67,533
– – 2.07% 23
2019
Q2 		$2.72M Sell
67,533
-1,367
-2% -$44.7K 2.03% 24
2019
Q1 		$2.27M Sell
68,900
-5,000
-7% -$118K 1.75% 26
2018
Q4 		$1.54M Buy
73,900
+20,000
+37% +$419K 1.35% 33
2018
Q3 		$948K Buy
+53,900
New +$904K 0.74% 37

Other funds holding KRYS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

S Squared Technology's KRYS Position: Q1 2026 in Review

S Squared Technology reduced its Krystal Biotech (KRYS) stake by 10% in Q1 2026, selling an estimated $2.66M and leaving 86,215 shares worth $22.3M. The position accounts for 8.43% of the portfolio, ranked #2.

S Squared Technology first reported a position in KRYS in Q3 2018 and has held it in 31 quarters since. The position peaked at $23.7M in Q4 2025. 367 funds tracked by Wall St. Rank hold KRYS as of Q1 2026.

  • S Squared Technology held 86,215 shares of Krystal Biotech worth $22.3M as of Q1 2026.
  • S Squared Technology sold 10,000 Krystal Biotech shares in Q1 2026, an estimated $2.66M.
  • Krystal Biotech made up 8.43% of S Squared Technology's portfolio in Q1 2026, its #2 holding.
  • S Squared Technology first reported a position in Krystal Biotech in Q3 2018 and has held it in 31 quarters since.
  • S Squared Technology's Krystal Biotech position peaked at $23.7M in Q4 2025.
  • 367 funds tracked by Wall St. Rank held Krystal Biotech as of Q1 2026.

Based on S Squared Technology's 13F filing for Q1 2026, filed 14 May 2026.